pt-141
Melanocortin receptor agonists · 7 suppliers · $3.30 to $6.80 per mg · 10 registered studies · 109 indexed papers
This page holds two records that were compiled separately. The research figures below come from the public registries named under each one, each read on the date printed beside it. The supplier prices at the foot were read on the suppliers own sites on the dates in that table. Nothing here was produced by this publication measuring anything.
Identity and computed properties
PubChem holds this compound as CID 9941379, molecular formula C50H68N14O10, average mass 1025.2 daltons and monoisotopic mass 1024.5243 daltons, read on 2026-09-19. Those masses are computed from the deposited structure and were not measured on any material, so they are the expected value an identity check compares against rather than evidence about any vial.
The title that record carries for the CID is Bremelanotide. Its synonym list runs to 54 entries. Among them: PT-141.
Receptors the literature describes
No published paper this search reached describes a receptor this compound acts at.
The registered trial record
An intervention search of clinicaltrials.gov for the term bremelanotide, read on 2026-09-19, returned 10 registered studies: 1 phase 1, 4 phase 2, 3 phase 3 and 2 phase 4.
Palatin Technologies, Inc is lead sponsor on 6 of the 10 records. The remaining 4 name 4 other organizations.
On the date read, the statuses those records carried were 9 completed and 1 active not recruiting.
The earliest record the search returns is NCT00425256, first submitted 2007-01-18. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.
Registry counts measure registration, not knowledge.
The publication record
PubMed answered 109 records for the term bremelanotide on 2026-09-19. Of those, 15 carry a clinical-trial publication type, and 2 of those carry Clinical Trial, Phase III. 56 carry the publication type Review, which is other people reading the rest.
PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.
Regulatory status
The Drugs@FDA database holds application NDA 210557 under this name, sponsor COSETTE. Its listed product is marked Prescription in the same database.
Findings, as published reports recorded them
This block was compiled and no finding from a named publication was reached.
Adverse events, as published reports recorded them
This block was compiled and no adverse event from a named publication was reached.
Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.
Who it is not given to
labelTwo groups must not be given Vyleesi, the approved product. People whose high blood pressure is not under control, and people with known heart disease. That is the entire list on the labelVYLEESI label · read 2026-09-19
Vyleesi is a prescription autoinjector with a measured dose. Powder sold as PT-141 is not that product, and nobody has checked it against that label.read 2026-09-19
Every row is a price read on that supplier's own site, divided by the milligrams it buys. Cheapest first, which is not a ranking of quality: the columns beside the rate show what this publication could confirm about the evidence behind it. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
Vendor comparison
| Per mg | Price | Supplier | Certificate checkable | Caution on record | What the figure is |
|---|---|---|---|---|---|
| $3.30per mg | $33.0010mg | GenPeptiderecord → | not transcribed | not transcribed | single vial current priceread 2026-08-20 |
| $3.50per mg | $34.9910mg | Atomix Researchrecord → | not transcribed | not transcribed | discounted from 39.99read 2026-08-23 |
| $3.50per mg | $34.9910mg | NeuroPept Labsrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $3.50per mg | $35.0010mg | Arcane Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $5.00per mg | $50.0010mg | Grey Research Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-25 |
| $6.50per mg | $65.0010mg | Improved Peptidesrecord → | not transcribed | not transcribed | single vial current priceread 2026-08-26 |
| $6.80per mg | $68.0010mg | BulkGLPrecord → | not transcribed | not transcribed | single listed unit, current priceread 2026-08-26 |
Read between 2026-08-20 and 2026-08-26. Prices move and these were read once.
Sources
Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-19. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-19. Formula and computed mass: PubChem, the CID printed above, read 2026-09-19. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-19.
The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.
- PubChem compound record, CID 9941379 read 2026-09-19
- Food and Drug Administration label record, openFDA drug label endpoint, pt-141 read 2026-09-19